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Drug products not only contain “actives” that confer the intended therapeutic benefits 
such as pain relief or act on particular part of the body, but contain other materials that 
are also “functional” with respect to the drug product. These are known as excipients 
and specific functionality which they confer to a particular product is independent 
upon the process used to add the excipient to the formulation and its exact location 
within the final dosage form. Introduction of novel drug delivery systems and new drug 
moieties lead to the need for new excipients with varied characteristics. Development 
of new excipient entities and their evaluation is a costly procedure; modification 
of existing excipients is very easy, more economical and less time consuming. The 
development of excipients that are capable of fulfilling multifunctional roles such as 
enhancing drug bioavailability and drug stability as well as controlling the release of 
the drug according to the therapeutic needs is one of the most important prerequisites 
for further progress in the design of novel drug delivery systems. The main focus 
of this article is on synthetic novel excipients that perform multiple functions in 
pharmaceutical formulations.
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1 INTRODUCTION
Therapeutic moieties cannot be administrated as such, so they are modified to various dosage forms for the reasons of patient compliance, dose accuracy and consistency, improving bioavailability, aesthetics and 
reduction of side effects (Prasanna et al., 2011). Excipients are the fundamental 
requirements to these modifications allowing formulation scientists to achieve 
their objectives. Excipients in brief can be defined as “The components of a 
formulation other than the active ingredient” (Parker et al, 2009). As compounds 
become more challenging to formulate, new excipients are needed to enable 
the delivery, manufacture and development of these compounds. Conventional 
excipients have been replaced with sophisticated compounds that fulfill multi-
functional roles in modern pharmaceutical dosage forms such as improvement 
of the stability and bioavailability of the active ingredient, enhancement of 
patient acceptability and performance of technological functions that ensure 
ease of manufacture (Steinberg et al, 1996 and Pifferi et al, 2003).
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1.1 Need of novel excipients
The excipients industry to date has been an extension of the food industry 
(Steinberg et al, 2001). Moreover, excipients are products of the food industry, 
which has helped maintain a good safety profile. Increasing regulatory 
pressure on purity, safety, and standardization of the excipients has catalyzed 
the formation of an international body, the International Pharmaceutical 
Excipients Council (IPEC) (http://www.ipecamericas.org). IPEC is a tripartite 
council with representation from the United States, Europe, and Japan; and has 
made efforts to harmonize requirements for purity and functionality testing 
(Blecher, 1993). The development of new excipients to date has been market 
driven (i.e., excipients are developed in response to market demand) rather 
than marketing driven (i.e., excipients are developed first and market demand is 
created through marketing strategies) and has not seen much activity as shown 
by the fact that, for the past many years, not a single new chemical excipient 
has been introduced into the market. The primary reason for this lack of new 
chemical excipients is the relatively high cost involved in excipients discovery 
and development. However, with the increasing number of new drug moieties 
with varying physicochemical and stability properties, there is growing 
pressure on formulators to search for new excipients to achieve the desired set 
of functionalities. The reasons to develop new excipients are following:
Effective use of existing excipients: a. Identification of new applications for 
the existing excipients is a relatively inexpensive and less time involving 
process as compared to an entirely new development. Chitosan is one 
of such existing excipients, which has found new applications in recent 
years. Modified chitosan with silicon dioxide is a new excipient developed 
based on coprecipitation of chitosan and silica which can be used as a 
superdisintegrant (Rashid et al, 2008) with improved flow and compaction 
properties. It also acts as filler (El-Barghouthi et al, 2008).
Excipients with desirable properties: b. There are a number of existing 
excipients which lack some of the desirable properties required in some 
formulations, viz., soluble tablets, in which an ideal lubricant should be 
water soluble with effectiveness similar to that of magnesium stearate. 
(http://www.fda.gov/cder/guidance/index)
Drugs developed by genetic engineering: c. As new drugs are being 
developed, their compatibility with the existing excipients sometimes 
poses a big question. Hence, new excipients will be necessary to overcome 
these problems. The drugs of protein and peptide class require stabilizers 
of a different nature when compared to that of conventional oral solid 
dosage forms.
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Advances in production process and equipment: d. The developments 
or improvements in pharmaceutical process and equipments, particularly 
increase in production rates at low cost, lead to the need for new 
excipients. The newly developed tablet machines require materials with 
better compressibility because they operate with shorter dwell and contact 
times, as compared to early machines that require materials with good 
flow properties.
Patient or subject compliance: e. Some excipients, which are used now-
a-days, are unacceptable for the reasons of patient safety and comfort. 
Lactose intolerance occurs in persons, who are deficient in the enzyme 
lactase, leading to abdominal cramps, diarrhea, distension and flatulence.
Specialized drug delivery systems: f. The development of novel or 
specialized drug delivery systems requires the use of special excipients. 
Metered dose inhalation devices require excipients of a particular size 
grade and development of mucoadhesive preparations necessitated the 
utilization of new bio adhesive polymers (Buckton, 2008; Veillard, 1991).
1.2 Advances in formulations and drug delivery systems
The advances in formulations and drug delivery systems lead to development of 
new or modified forms of existing excipients. The various areas exploring the 
development are classified into (a) improvements to immediate and controlled 
release dosage forms; (b) nanotechnology; (c) specialized delivery systems; 
(d) biologics (www.meggle-pharma.com)
Improvements to immediate and controlled release dosage forms: a. 
New excipient grades, with better performance or tighter controls are 
also developed for pharmaceutical use. Hydroxypropyl methylcellulose 
(HPMC) is a commonly used hydrophilic polymer to achieve matrix 
based controlled release. However, direct compression of HPMC-based 
formulations is challenging because HPMC may impart poor flow 
properties to the formulation, causing problems during high-speed tablet 
manufacturing (Sheskey et al, 1996). Thus, granulation of HPMC-based 
formulations is usually required. Granulation process variables can exert 
a significant impact on the dissolution characteristics of HPMC based 
tablets. Huang et al found that when HPMC K15M matrix tablets were 
prepared by wet-granulation; the tablet hardness, distribution of HPMC 
within the tablet (intergranular and intragranular), and the amount of 
water added in the wet granulation step, all have a significant impact on 
dissolution and release profiles of the drug from the tablets (Huang et al, 
2003). Recently, new grades of HPMC K4M and K100M DC have been 
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designed to possess properties such as larger particle sizes and better flow 
properties to facilitate direct compression, thus avoiding the need for 
granulation. Tableting trials with the new HPMC DC grades showed lower 
tablet weight variability with similar release using model drugs compared 
to the CR grades (Ender et al, 2007).
Nanotechnology: b. Recent advances in nanotechnology for drug delivery 
are divided into 4 areas. Firstly, advances to improve manufacturability 
and robustness of existing technologies (e.g. liposomes, nanoparticles and 
nanocrystals). Secondly, strategies to improve stability of the nanoscale 
systems in vivo and in vitro are researched. For example, PEGylation 
and alternatives to PEGylation to improve in vivo stability and reduce 
immunogenicity are explored. Thirdly, new materials are designed to 
obtain improved properties, such as derivatization of existing polymers 
like poloxamer to optimize drug solubilization or customized drug release 
at targeted sites. Fourthly, numerous new targeting functionalities have 
been designed by many to improve specificity to target organs. As many 
drug candidates are either poorly water soluble or challenging to deliver, 
there is a need for new solubilizers and specialized drug delivery systems 
to enable solubilization and bioavailability. Polyoxyl 15 Hydroxystearate 
is an example of a new solubilizer that also exhibits good tolerability over 
traditional solubilizers like polysorbate 80. It is also the first new excipient 
to be evaluated under the new IPEC Novel Excipient Safety Evaluation 
Procedure, established in 2007 (Velagaleti, 2009). Cyclodextrins are also 
used to achieve drug solubilization by complexation. To date, cyclodextrins 
have been used in the formulations of 34 marketed products (Brewster 
et al, 2007). Recent advances in cyclodextrins research are focused on 
designing new derivatives with “customized” substitutions, substitutions 
to increase solubility and lower toxicity, and scale-up of the inclusion 
complexes manufacturing.
Specialized Delivery Systems: c. Solid dispersions are also a hot research 
field because they have shown much promise to improve the dissolution 
and bioavailability of poorly water soluble drugs. The introduction of new 
polymeric carriers such as Hypromellose acetate succinate (HPMCAS), 
copolymers based on dimethylaminoethyl methacrylate, butyl methacrylate 
and methyl methacrylate, poly (vinylpyrrolidone-vinyl acetate) (PVP-VA), 
lauroyl macrogol glycerides (polyoxylglycerides) have further advanced 
this field. These excipients provide thermoplastic and thermal stability 
to solid dispersions and have also improved manufacturability. Taste 
masking is important in the development of paediatric formulations and 
dosage forms like rapidly disintegrating tablets containing bitter drugs. 







Journal of Pharmaceutical Technology, Research and Management (JPTRM), Volume 1, May 2013
One mechanism of taste masking is to prevent dissolution of the drug in 
the mouth and contacting the taste buds, and only releasing drug in the 
stomach or beyond in the gastrointestinal tract. A newly available methyl 
methacrylate diethylaminoethyl methacrylate (6:4) copolymer dispersion 
with macrogol cetostearylether and sodium lauryl sulfate included as 
stabilizers in the formulation which is based on this principle. The co-
polymer being pH-sensitive effectively prevents drug dissolution under 
neutral conditions in the saliva, with immediate release under acidic 
conditions of the stomach (www.pharma-ingredients.basf.com).
Biologics: d. Recent advances in biologics are focused primarily on 
parenteral routes of administration. Materials have been investigated 
for greater stabilization (in vitro and in vivo), reduced frequency of 
administration, achievement of high doses and improved manufacturability 
of biologic formulations such as maintaining protein activity on scale-up. 
Major classes of delivery systems used in biologics formulation include 
microspheres (PLGA-based, Chitosan-based), liposomes (PEGylated 
lipids) and hydrogels (modified dextran and starch-based). In the area of 
sIRNA delivery systems for systemic administration, three major groups 
of systems based on material are used (David et al, 2010). The first are 
the lipid systems, including neutral liposomes composed of dioleyl-
glycerophosphatidylcholine (DOPC) and cationic liposomes composed of 
1, 2-Dioleoyl-3-trimethylammonium-propane (DOTAP). The second are 
the systems that use polymers, such as natural polymers (e.g. atelocollagen 
and cyclodextrins) and synthetic polymers (e.g. Polyethyleniemine (PEI). 
Lastly, peptides and proteins, like antibody-protamine fusion proteins are 
also used to formulate sIRNA. 
1.3 Synthetic excipients
Synthetic excipients are used in the manufacture of tablets to bind the tablet 
together, reduce die wall friction between the tablet and the tableting press, 
control pH balance, and to disintegrate the tablet in the stomach once it has been 
ingested. In parenterals, synthetic excipients are used as solubilization agents to 
make actives more soluble, and therefore, more deliverable (Russell, 2004).
The advancements in the area of synthetic excipients are discussed under 
coprocessed, multifunctional and high functionality excipients.
1.4 Coprocessed Excipients
A coprocessed excipient is a combination of two or more compendial or 
non compendial excipients designed to physically modify their properties in 
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manner not achievable by simple physical mixing, and without significant 
chemical change. Coprocessed excipients are used mainly in solid dosage 
forms such as tablets, capsules, powder and in liquid dosage forms such as 
emulsions, suspensions, injections and in semisolid dosage forms such as 
creams, ointments and pastes (Chaudhary et al, 2012). 
Principle of coprocessing: Basic fundamental of coprocessing is based on 
particle engineering. Solid substances are characterized by three levels of solid 
state- molecular, particle, and bulk level. These levels are closely linked to one 
another, with the changes in one level reflecting in another level. The molecular 
level comprises the arrangement of individual molecules in the crystal lattice 
and includes phenomena such as polymorphism, pseudo-polymorphism, and 
the amorphous state. Particle level comprises individual particle properties 
such as shape, size, surface area, and porosity. The bulk level is composed of an 
ensemble of particles and properties such as flow ability, compressibility, and 
dilution potential, which are critical factors in the performance of excipients. 
Coprocessing based on the novel concept of two or more excipients interacting at 
the sub particle level, the objective of which is to provide a synergy of functionality 
improvements as well as masking the undesirable properties of individual 
excipients. The availability of a large number of excipients for coprocessing 
ensures numerous possibilities to produce tailor-made “designer excipients” to 
address specific functionality requirements (Marwaha et al, 2010).
Coprocessing of excipients: The actual process of developing a coprocessed 
excipient involves the following steps (Bansal et al, 2004):
Identifying the group of excipients to be coprocessed by carefully studying •	
the material characteristics and functionality requirements.
Selecting the proportions of various excipients.•	
Assessing the particle size required for coprocessing. This is especially •	
important when one of the components is processed in a dispersed phase. 
Post processing the particle size of the latter depends on its initial particle 
size.
Selecting a suitable process of drying such as spray or flash drying.•	
Optimizing the process (because even this can contribute to functionality •	
variations).
Advantages of coprocessing 
Improved Flow Properties and compressibility: e. Controlled optimal 
particle size and particle-size distribution ensures superior flow properties 
of co-processed excipients without the need to add glidants. The 
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volumetric flow properties of SMCC were studied in comparison with 
MCC. The particle-size range of these excipients was found to be similar 
to those of the parent excipients, but the flow of coprocessed excipients 
was better than the flow of simple physical mixtures. A comparison of 
the flow properties of cellactose was also performed. The angle of repose 
and the Hausner’s ratio were measured, and cellactose was found to 
have better flow characteristics than lactose or a mixture of cellulose and 
lactose (York, 1992). These have been used mainly in direct compression 
tableting because in this process there is a net increase in the flow properties 
and compressibility profiles and the excipient formed is a filler-binder.( 
(Marwaha et al, 2010)
Better dilution potential: f. Dilution potential is the ability of the excipient 
to retain its compressibility even when diluted with another material. 
Most active drug substances are poorly compressible, and as a result, 
excipients must have better compressibility properties to retain good 
compaction even when diluted with a poorly compressible agent. (Flores 
et al, 2000).
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Table 2: Application of Coprocessed excipients (Chaudhary et al., 2010)
Excipients Drug Approach used Outcome
Ludiflash
(Sandra, 2007)
Risperidone Direct compression Disintegration time of 27 sec
Pharmaburst
(Cecil WP 2007)
Famotidine Taste masking 
microsphere using 
spray drying
Disintegration in 30 seconds 
with improved taste.
F-MELT
(Fuji health science, 
2008)
Acetaminophen Direct compression 
using 10 % to 65% 
w/w
Good mouth feel and excellent 









Metformin Wet granulation Disintegration time of 85 s. 




Placebo Direct compression Even without superdisintegrants, 
tablets containing both isomalt 





Sumatriptan Direct compression Disintegration time of 45 sec, 
100% drug release in 10 min
Fill weight variation: g. In general, materials for direct compression tend to show 
high fill weight variations as a result of poor flow properties, but coprocessed 
excipients, when compared with simple mixtures or parent materials, have 
been shown to have fewer fill weight variation problems. The primary reason 
for this phenomenon is the impregnation of one particle into the matrix of 
another, which reduces the rough particle surfaces and creates a near optimal 
size distribution, causing better flow properties. Fill weight variation tends to 
be more prominent with high-speed compression machines.
Reduced lubricant sensitivity: h. Most coprocessed products consist of a 
relatively large amount of brittle material such as lactose monohydrate and 
a smaller amount of plastic material such as cellulose that is fixed between 
or on the particles of the brittle material. The plastic material provides 
good bonding properties because it creates a continuous matrix with a 
large surface for bonding. The large amount of brittle material provides 
low lubricant sensitivity because it prevents the formation of a coherent 
lubricant network by forming newly exposed surfaces upon compression, 
thus breaking up the lubricant network. Various examples of coprocessed 
directly compressible excipients and application of these excipients are 
depicted in Table 1 and 2 respectively. 
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Technologies used for coprocessed excipients 
Roller compaction: a. In the roller compaction process, powder blends first 
pass a feeding zone, where most of the rearrangement occurs (Chougule 
et al, 2012). The dense powders then go through a compaction zone, 
where increasing force is being exerted by two counter rotating rolls. 
As the pressure goes up further into the compaction zone, the particles 
deform, fragment, and bond to form ribbons. Roller compaction is widely 
applied to dry granulation. It offers many superior characteristics e.g. good 
control of process and cost advantages compared to wet granulation. As no 
liquid or drying is involved, this process is more suitable for water or heat 
sensitive drugs (Reynolds et al, 2010). Compared to direct compression, 
roller compaction can handle high drug loading, improve flow and 
content uniformity and prevent segregation. Like any other processes, dry 
granulation has its own issues, such as loss of compactibility of dissolution 
problem. A systematic approach of formulation and process development 
is the key to high quality drug products. At high drug loading, the 
compactibility and flow ability of drug substance will be critical for roller 
compaction and tableting processes (Miller, 1997). Different excipients 
need to be evaluated in formulation development to achieve desirable 
chemical stability, tablet properties, and process control.
Wet granulation: b. Wet granulation is a process still widely used in the 
pharmaceutical industry. It has not been replaced by direct compression 
technology, partly because of development cost considerations and habits, 
and partly because it remains in some cases an attractive technique. The 
process continues until all the powder has been agglomerated, and it needs 
to be stabilized as far as moisture balance is concerned. The equilibrium 
may not be constant, however, as the moisture content of the granules 
could be increasing slightly throughout the process, and the trajectories of 
the particles may change with changes in the density of the agglomerated 
powder bed. Complete drying is quickly achieved in the hot air stream 
when binder spraying is stopped (Hapgood et al, 2009). The drying step 
traditionally takes place after transferring the damp mass into another piece 
of equipment (fluid bed dryer), but the use of single-pot technology (drying 
in place) is now spreading. The granules formed are understandably denser 
than those obtained in fluid bed granulation (York et al, 2009). 
Spray drying: c. This technique enables the transformation of feed from a 
fluid state into dried particulate form by spraying the feed into a hot drying 
medium. It is a continuous particle processing drying operation. The feed 
can be a solution, suspension, dispersion or emulsion. The dried product 
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can be in the form of powders, granules or agglomerates depending upon 
the physical and chemical properties of the feed, the dryer design and final 
powder properties desired (http://www.ich.org/LOB/media). Spray drying 
process (Gohel, 2005) mainly involves five steps:
 Concentration:i.  Feedstock is normally concentrated prior to 
introduction into the spray dryer.
Atomization:ii.  The atomization stage creates the optimum condition 
for evaporation to a
dried product having the desired characteristics.iii. 
Droplet-air contactiv. : In the chamber, atomized liquid is brought into 
contact with hot gas, resulting in the evaporation of 95% of the water 
contained in the droplets in a matter of a few seconds.
Droplet dryingv. : Moisture evaporation takes place in two stages: 
during the first stage, there is sufficient moisture in the drop to replace 
the liquid evaporated at the surface and evaporation takes place at 
a relatively constant rate. The second stage begins when there is no 
longer enough moisture to maintain saturated conditions at the droplet 
surface, causing a dried shell to form at the surface. Evaporation 
then depends on the diffusion of moisture through the shell, which is 
increasing in thickness.
Separationvi. : Cyclones, bag filters, and electrostatic precipitators may 
be used for the final separation stage. Wet Scrubbers are often used 
to purify and cool the air so that it can be released to atmosphere. 
Spray drying process have advantages that can be designed to virtually 
any capacity required. Feed rates range from a few pounds per hour 
to over 100 tons per hour. Operation is continuous and adaptable to 
full automatic control. It can be used with both heat resistant and 
heat sensitive products. Nearly spherical particles can be produced. 
There are some limitation that includes limited versatility in producing 
particles or structures with the complex morphologies, and rapid drug 
release rates often exhibiting a burst effect (Patel et al, 2009). 
Co-spray drying: d. Incorporation of ingredients under dry or solid form 
during drying process, by atomizing active compounds in solution or 
under the form of emulsion. The process is advantageous in many ways 
such as- Possibility to associate non-miscible products in continuous 
operation, Possibility to blend and dry simultaneously soluble and 
insoluble compounds, Possibility to fix and protect sensitive active 
compounds on neutral carrier (Patel et al, 2009). This leads to improved 
hardness and compressibility, better uniformity than granulated in actives, 
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enhanced machine tableting speed, lesser disintegration time, consistent 
physical parameters of excipients ensuring sturdy formulation, no need to 
maintain inventory of various excipients, cost saving due to elimination of 
wet granulation production steps, productivity increase due to increased 
machine speed and cost saving in rework expenses. But there are some 
limitation that includes limited versatility in producing particles or 
structures with the complex morphologies, and rapid drug release rates 
often exhibiting a burst effect.
Solvent evaporation: e. This process is carried out in a liquid manufacturing 
vehicle. The coating excipient is dissolved in a volatile solvent, which is 
immiscible with the liquid manufacturing vehicle phase. A core excipient 
material to be microencapsulated is dissolved or dispersed in the coating 
polymer solution. With agitation, the core coating material mixture 
is dispersed in the liquid manufacturing vehicle phase to obtain the 
appropriate size microcapsule. The mixture is then heated (if necessary) to 
evaporate the solvent. Once all the solvent is evaporated, the liquid vehicle 
temperature is reduced to ambient temperature (if required) with continued 
agitation. At this stage, the microcapsules can be used in suspension form, 
coated on to substrates or isolated as powders. The core materials may be 
either water -soluble or water - insoluble materials.
Melt extrusion: f. Melt extrusion is a process of formation of small beads/ 
pellets from the molten mass which is extruded through extruder (http://
www.Zeusinc.com). This technique is reproducible, less time consuming 
and moreover, complicate and intricate shapes are possible. But equipment 
and die costs are high.
Crystallization: g. Crystallization is the (natural or artificial) process of 
formation of solid crystals precipitating from a solution, melt or more 
rarely deposited directly from a gas. Crystallization is also a chemical 
solid–liquid separation technique, in which mass transfer of a solute from 
the liquid solution to a pure solid crystalline phase occurs (Blecher, 1993). 
For crystallization to occur from a solution it must be supersaturated. This 
means that the solution has to contain more solute entities (molecules 
orisons) dissolved than it would contain under the equilibrium (saturated 
solution). This can be achieved by various methods such as: solution cooling, 
addition of a second solvent to reduce the solubility of the solute (technique 
known as antisolvent or drown-out), chemical reaction and change in pH 
being the most common methods used in industrial practice.
Agglomeration: h. Agglomeration is the act or process of forming or 
crystallizing into grains. Granules typically have a size range between 
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0.2 to 4.0 mm depending on their subsequent use. Agglomeration of 
powders is widely used to improve physical properties like: wettability, 
flowability, bulk density and product appearance (Blecher, 1993). Two 
types of granulation technologies are employed, namely, wet granulation 
and dry granulation. Wet granulation is the more preferred method for 
coprocessing.
1.5 Multifunctional Excipients
Multifunctional excipients are a class of excipients that includes preprocessed 
and coprocessed excipients that provide added functionalities to the formulation 
(for example, Silicified Micro-Crystalline Cellulose, which is a processed 
combination of MCC and colloidal silicon dioxide). These functionalities 
include flowability, compressibility, particle size distribution, shape, porosity, 
etc. The term multifunctional excipient is also extended to products that 
serve multiple roles in the formulation e.g. Ludipress, which is co-processed 
product containing lactose, Kollidon and Kollidon-CL, serves the role of 
directly compressible diluent with binder and disintegrant properties (www.
contractpharm.com).
Multifunctional excipients can be obtained by developing a new excipient 
(such as cross-linked polymers) or by developing new grades of existing 
excipients; modification in the processing leads to changes in the particle 
size distribution, particle shape and morphology and porosity. Traditionally, 
industry stays away from developing a new excipient altogether, due to the cost 
involved and problems faced in getting regulatory approvals. The change in the 
manufacturing process of an excipient along with addition of minor amount 
of another known excipient results in a product that has enhanced physical 
characteristics leading to added functionality. Combining of known excipients 
at sub-particle level (also known as co-processing) leads to excipients with 
modified properties like enhanced surface area, increased porosity, enhanced 
compressibility, good flowability etc. Co-processed excipients are also suitable 
for direct compression and thus help in simplification of tablet manufacturing. 
The reason for enhanced compressibility can be drawn from the fact that most of 
the co-processed excipients primarily consist of a large amount of brittle material 
and a smaller amount of plastic material. Thus, a co-processed material displays 
the property, which is a combination of plasticity as well as brittleness.
1.5.1 Recent Studies Using Multifunctional Excipients
Rice Germ Oil (RGO) as multifunctional excipient: a. Self-
microemulsifying drug delivery system (SMEDDS) of tacrolimus (TAC) 
was formulated with RGO, an indigenous source of gamma-oryzanol. 
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Being the same biological source, RGO and rice bran oil (RBO) were 
compared and it was found that RGO have more solubilization potential 
for TAC (2.2-fold) as well as higher antioxidant activity (8.06-fold) than 
the RBO. TAC-SMEDDS was prepared using RGO/Capmul PG8 (2:3) 
as an oil phase, Cremophore EL as a surfactant, and Transcutol P as a 
cosurfactant. The in vitro dissolution studies showed complete and rapid 
drug release in 30 min compared to a plain drug (<5%) and marketed 
capsule (<50%). Thus, gamma-oryzanol-enriched RGO acts as a potential 
multifunctional excipient for lipid formulations (Pawar et al, 2012).
Sugar end-capped Poly-D, L-lactides as excipients: b. Sugar end-capped 
poly-D, L-lactide (SPDLA) polymers were investigated as a potential 
release controlling excipient in oral sustained release matrix tablets. The 
SPDLA polymers were obtained by a catalytic ring-opening polymerization 
technique using methyl α-Dglucopyranoside as a multifunctional initiator 
in the polymerization. Polymers of different molecular weights were 
synthesized by varying molar ratios of monomer/catalyst. The matrix tablets 
were prepared by direct compression technique from the binary mixtures 
of SPDLA and microcrystalline cellulose, and theophylline was used as 
a model drug. The drug release was the fastest with the lowest molecular 
weight SPDLA grade, and the drug release followed zero-order rate. In 
conclusion, SPDLAs are a novel type of drug carrier polymers applicable 
in oral controlled drug delivery systems (Vuorinen et al, 2009).
O-Phospho-L-Serine, multi-functional excipient: c. Factor VIII (FVIII) 
is an important cofactor in the blood coagulation cascade. A deficiency 
or dysfunction of FVIII causes hemophilia A, a life-threatening bleeding 
disorder. FVIII circulates in plasma as a heterodimer comprising 6domains 
(heavy chain, A1-A2-B and light chain, A3-C1-C2). Replacement therapy 
using FVIII is the leading therapy in the management of hemophilia. This 
research work investigated the effect of O-phospho-L-serine (OPLS), which 
binds to the lipid binding region, on the immunogenicity of B domain 
deleted recombinant factor VIII (BDDrFVIII). Sandwich enzyme-linked 
immunosorbent assay (ELISA) studies showed that OPLS specifically bind 
to the lipid binding region. Overall, the study demonstrated that specific 
molecular interaction of BDDrFVIII occurs with OPLS resulting in less 
protein aggregation and less immunogenicity (Miclea et al, 2007).
Modification of the permeability of starch by processing with d. 
magnesium silicate: Starch processed with magnesium silicate, using 
co-precipitation or dry granulation, can be used as a multifunctional 
excipient with the required binding and disintegration properties. Powder 
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compression using Kawakita analysis confirmed the higher plasticity and 
lower degree of rearrangement of starch- magnesium silicate resulting from 
co-precipitation compared to dry granulation. In addition, co-precipitation 
imparts high surface micro-irregularities as evidenced by SEM analysis. 
Formulation of a high strength model drug with starch- magnesium silicate 
illustrated the efficiency of the highly permeable starch- magnesium 
silicate in attaining quick drug release when compared to formulations 
with commercially available modified starch (Rashid et al, 2011).
Co-processed MCC-Eudragit® E excipients for extrusion-e. 
spheronization: This study investigates the extrusion–spheronization 
performance of some mixtures of co-processed microcrystalline cellulose 
and Eudragit® E (as excipients) and sorbitol (as soluble filler-disintegrant. 
The pellets prepared with co-processed MCC-Eudragit_ E and sorbitol 
show a drug dissolution rate dependent on the content of Eudragit_ E in 
the co-processed excipient and on the proportion of sorbitol incorporated. 
Furthermore, the pellets made with co-processed MCC-Eudragit®E 
incorporating the higher proportion of sorbitol (50%) show a very 
high dissolution rate of hydrochlorothiazide (HCT) and undergo rapid 
disintegration in the dissolution medium (Goyanes et al,2011).
Modified celluloses- Multifunctional excipients: f. The assessment of 
different celluloses (native cellulose, powdered cellulose, UICEL B 
UICEL S, Microcrystalline cellulose, UICEL XL) with respect to their 
suitability as excipients in rapidly dissolving immediate release tablets 
was the main scope of this research work. Based on different models six 
celluloses were evaluated. All tested materials were suitable for rapidly 
dissolving immediate release tablets independent of the relative density 
and drug load (Medina et al, 2006).
Chitin metal silicate (CMS) co-precipitate: g. The CMS co-precipitates 
have the potential to be used as a single filler tablet excipient with 
a multifunction action. This might make the formulation simpler by 
introducing one excipient with double or triple function instead of two 
or more excipients with less probability of incompatibility between 
formulation ingredients. The compressibility of poorly compressible drugs 
like Metronidazole and spironolactone was highly improved using CMS 
co precipitates (Rashid et al, 2008).
Selected polysaccharide hydrogels: h. Polysaccharide hydrogels from the 
seeds of Tamarindus indicia and from the trunk of Prunus Amygdalus 
were selected for physicochemical characterization and microbial 
load determination to establish them as pharmaceutical excipients. The 
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pharmaceutical properties such as density, porosity, packing arrangement, 
flow was found to be good for using them as pharmaceutical excipients. 
It was concluded that selected hydrogels had promising properties for 
application as multifunctional excipients (Rohokale et al, 2012). 
1.5.2 Examples Of Innovative Multifunctional Excipients
galenIQTM- The smart excipient: a. GalenIQTM- combines a multitude of 
outstanding characteristics and is suitable for a wide range of pharmaceutical 
applications. galenIQTM can be used as more than just a bulk excipient. 
It also serves as an anti-caking agent, anti-humectant, stabilizer or oral 
care and taste agent to mention just a few additional functions. galenIQ™ 
(pharmaceutical grade isomalt) is a filler/binder, tablet &capsule diluent, 
coating agent& it complies with the isomalt monographs of the current Ph. 
Eur., BP,USP-NF and is approved for use in Japan and China. galen IQ™ 
is manufactured under cGMP guidelines for pharmaceutical excipients 
(IPEC-PQG) & under its generic name „isomalt“, galenIQ™is listed in all 
major reference books for pharmaceutical excipients and in the US FDA/
CDER Inactive Ingredient Database (www.galenIQ.com).
 Physicochemical properties of galenIQ™
 Different solubilities, very low hygroscopic, highly resistant against 
enzymatic and acidic degradation, heat stable; melting range: 145 to 150 
°C, no reaction with amino groups, no incompatibilities with API‘s faced, 
unique morphology, equilibrated sweetness, non-carcinogenic. 
MCC SANAQ®burst: b. MCC SANAQ®burst consists of 100%pure MCC 
(with no additional excipients).The fast disintegration is kept even after 
spheronization and extrusion. It is a unique multifunctional excipient act 
as binder, filler and superdisintegrant. 
NEUSILIN: c. Neusilin® is a synthetic, amorphous form of Magnesium 
Aluminometasilicate (MAS). It is a multifunctional excipient that can be 
used in both direct compression and wet granulation of solid dosage forms. 
Neusilin® is widelyused for improvement of the quality of tablets, powder, 
granules and capsules. Neusilin® does not develop gels with aqueous 
solutions unlike other magnesium aluminium silicates (www.Neusilin.
com). Neusilin® occurs as a fine powder or as granules of Magnesium 









O.Neusilin® is amorphous, possesses very large 
specific surface area and has high oil and water adsorption capacity. It is 
superior in compressibility. It makes hard tablets at low compression force 
and in addition, at low concentrations can improve the hardness of other 
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filler and binder excipients. Compounding with Neusilin® helps to stabilize 
moisture sensitive as well as lipophilic API’s.It is stable against heat and has 
a long shelf life.It is available in various grades. The grades differ in their 
bulk density, water content, particle size and pH (Chakraborty et al, 2010).
 It is used as excipient for direct compression, oil adsorption of poorly 
water soluble actives, improves powder flowability, anti-caking agent for 
hygroscopic powders, stabilization of deliquescent drugs, low friability 
and less tablet rejections and smaller tablets with relevant hardness.
SYLOID® FP Multifunctional excipients: d. SYLOID® FP silica is 
efficient in many pharmaceutical applications due to its unique morphology. 
It has a highly developed network of meso-pores that provide access to 
the large surface area that defines its performance. The result is a product 
that is easy to incorporate, providing more uniform dispersion of actives 
and improved content uniformity and high adsorptive capacity - both for 
hydrophilic and hydrophobic compounds (Parker et al, 2009).
 It act as effective desiccant to increase the stability of moisture-sensitive 
active pharmaceutical ingredients (APIs),efficient conditioner for powder 
formulations used in suspensions, capillary wetting agent for better 
release and disintegration, contribution to the controlled release of active 
pharmaceutical ingredients and enhanced bioavailability. It is used as 
glidant, carrier for active ingredients, moisture scavenger/protector and 
used in tableting as well as Coating.
UNI-PURE™ WG Multifunctional Excipient: e. The optimum 
performance of UNI-PURE WG depends on several factors, including 
the physicochemical properties of the drug, the type of filler and the 
process used to make granules and tablet. In a given formulation, tablet 
performance is determinedly processing conditions (www.excipients.
com). It Improves solid dosage formulations and simplifies processing, 
multifunctional excipient swells in cold water for better processing, 
improves compressibility, wet granulation binder, reduce disintegration 
time and enhanced tablet properties.
Pharmaburst™“Quick Dissolve”: f. Pharmaburst is a coprocessed 
excipient system with specific excipients, which allows rapid disintegration 
and low adhesion to punch faces. It is also said to be a “Quick Dissolve” 
delivery system (www.SPIPharma.com). It is highly compactable, high 
loading in small tablet, smooth mouth feel, standard temperature humidity 
and cooling, rapid disintegration, uses USP/EP excipients, produced under 
cGMP, cost effective.
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Recombinant Albumin-g.  rAlbumin: A multifunctional excipient, 
rAlbumin acts to stabilize the drug product by reducing aggregation, 
oxidation, and surface adsorption. Particularly valuable for liquid 
formulations, rAlbumin can significantly decrease the attrition rate in 
formulation development and provides increased freedom to choose 
the best candidate for further development Novozymes has developed a 
range of recombinant human albumins (rAlbumins) specifically for the 
pharmaceutical industry. Manufactured in an animal-free process to the 
highest quality standards, Novozymes’ rAlbumins act as multifunctional 
excipients. Their use reduces the requirement for multiple excipients, such 
as SADs, and delivers a safe and consistent product that enhances the 
stability and performance of the customer’s drug product. The functional 
properties of rAlbumin as an effective excipient in three areas commonly 
affecting product stability are: Aggregation, Oxidation and Nonspecific 
adsorption. It also provides a comparison of the physiochemical properties 
of a range of commercially available albumins through detailed product 
analysis (Bharate et al,2010).
1.6 High Functionality Excipients (Hfe)
HFE are inactive ingredients that meet four unique criteria. Firstly, they 
are multifunctional. They do not perform a single function, like glidants, 
lubricants, anti-adherents, binders or disintegrants.HFE combine two or more 
functions through a single ingredient. Secondly, HFE have high inherent 
functional performance allowing for increased batch sizes and higher 
drug-loading, even at low usage levels. Thirdly, HFE require no complex 
processing, making them ideal for direct compression processes. Lastly, 
HFE impart their high inherent performance characteristics to the overall 
formulation. This last criterion is critical and separates HFE from other 
multi-functional excipients or conventional specialty excipients (Zeleznik et 
al, 2004).
PROSOLV SMCC (Silicified microcrystalline cellulose): Silicified 
microcrystalline cellulose – combines 98% microcrystalline cellulose 
(MCC) and 2% fumed colloidal silicon dioxide (CSD) in a patented 
coprocessed intimate mixture. PROSOLV provides significant functional 
performance and may be utilized in development of unique dosage forms 
for the branded generic market segment, providing substantial economic 
benefits with regard to revenue streams (Sherwood et al, 1998). It is accepted 
by US FDA, high drug loading and gives better flow, compatibility and 
disintegration.
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1.7 Recent Advancements in Synthetic Excipients
Starch 1500 (Partially pregelatinized maize starch): a. Starch 1500 is a 
unique pharmaceutical excipient combining several properties in a single 
product. Only Starch 1500performs the multiple functions of a binder, 
disintegrant, flow-aid and self-lubricant. It is extremely versatile, being 
effective in a variety of processing methods for solid oral dosage forms. 
Starch 1500 also exhibits synergy, enhancing the functionality of other 
commonly used excipients in formulations (www.colorcon.com). Starch 
1500 is manufactured exclusively for the pharmaceutical industry in 
dedicated cGMP facilities. The process involves a physical modification 
of the starch (no chemical additives or surfactants are used), resulting in 
the combined benefits of the soluble and insoluble functionality of Starch 
1500. Maize starch is composed of two polymers, amylose and amylopectin 
which are tightly bound in a specific sphero crystalline structure. Through 
partial pregelatinization, the bond between portions of the two polymers 
is broken, providing Starch 1500 with its unique properties. The process 
results in partial solubility, increased particle size, improved flow 
properties and compactibility. Colorcon’s unique manufacturing process 
results in the most effective functional balance for Starch 1500, providing 
good cold water binding and granulation properties, yet retaining effective 
tablet disintegrant properties. The physical structure of Starch 1500 
also imparts good compactibility, flow and lubrication capability. These 
multifunctional properties can be utilized in a variety of applications, 
including direct compaction, wet granulation, fluid bed granulation and 
capsule plug formation. The distinct benefits of Starch 1500 can bring 
significant process flexibility to solid dosage forms.
C*Pharm DC 9300 directly compressible starch: b. C*Pharm DC 9300 
combines the two main properties of both pregelatinized and native 
starch: strong binding and fast disintegration (Michaud et al, 2002).This 
new directly compressible starch appears as a white free-flowing powder 
composedof partly gelatinized agglomerated starch granules. One of the 
other very interesting properties of directly compressible starch is its 
aptitude to demonstrate synergies with other excipients such as lactose 
and microcrystalline cellulose. These two products are certainly some of 
the most widely used excipients in pharmaceutical formulations besides 
starch (Manudhane et al, 2010). The classification of modified starches is 
given in Table 3.
Captisol (Modified beta cyclodextrin): c. Captisol® was invented by 
scientists at the University of Kansas Higuchi Biosciences Center for use 
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Table 3: Classification of modified starches
Type of modification Products
1. Chemical modification 
(cross-linking, Substitution, 
Conversion)
Distarch phosphate Starch esters: Acetylated starch, starch 
phosphate,octenylsuccinate-treated starch. Starch ether: 
hydroxypropylated starch, carboxy methylated starch, 
cationized starch etc. Acid converted starch, oxidized 
starch, bleached Starch.
Pyroconversion (dextrinization): dextrin, British gum, etc.
2. Physical modification 
(Pregelatanization, Heat 
treatment, Radio treatement)
Pregelatinized starch Heat–moisture treated starch, 
annealed starch Radio treated starch
3. Enzymatic Modification Maltodextrins, cyclodextrin, amylose etc.
Figure 1: Chemical structure of Captisol (www.Captisol.com)
in drug development and formulation. Captisol® is a patent protected, 
uniquely modified cyclodextrin, whose chemical structure was rationally 
designed to maximize safety and optimize interaction to improve the 
solubility, stability, and bioavailability; to lessen the volatility, irritation, 
smell or taste. Captisol is a polyanionic beta-cyclodextrin derivative with 
a sodium sulfonate salt separated from the lipophilic cavity by a butyl 
ether spacer group, or sulfobutylether (SBE). Captisol is the trade name 
for CyDex’s SBE7 BETA –CD-preparation. The chemical structure of 
captisol is shown in Figure 1.
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Benefits of captisol over parent cyclodextrinsd. 
Straight forward biodistribution and elimination: i. Upon 
administration, the Captisol-drug complex rapidly dissociates. Captisol 
formulations are biocompatible and can be administered by numerous 
routes including parenteral and oral route. Captisol exhibits limited 
plasma protein binding and distributes to extracellular fluid.
Pharmacologically inactive: ii. Captisol produced no pharmacological 
effect on the cardiovascular system; autonomic or somatic functions; 
respiratory capacity; or fluid or electrolyte excretion upon I.V. 
administration in a variety of animal models (www.Captisol.com)
Ease of use: iii. Compared to other drug delivery technologies, Captisol 
is easy to use in your laboratory. Neutral, cationic and anionic drugs 
have been effectively complexed by Captisol. In contrast to other 
solubilisation technologies, the feasibility of Captisol can be rapidly 
assessed with a few simple experiments.
Marketed products using Captisol technologye. 
Captisol-enabled® Propylene Glycol-Free Melphalani. 
  Ligand’s Captisol-enableda. ® Melphalan program is a new IV formulation 
of Melphalan that has the potential to offer multiple advantages for 
clinicians and patients in the multiple myeloma transplant setting. 
Ligand’s formulation completely avoids the use of propylene glycol, 
which is used as a co-solvent in the current formulation of Melphalan 
(sold as Alkeran® for Injection), and has been reported to cause 
renal and cardiac side-effects that limit the ability to deliver higher 
quantities of intended therapeutic compounds. The use of Captisol® 
technology to reformulate Melphalan is anticipated to allow for longer 
administration durations and slower infusion rates, potentially enabling 
clinicians to safely achieve a higher dose intensity of per-transplant 
chemotherapy (www.Cydexinc.com).
CyDex : Captisol-Enabled Propofol Injectable Solution- New ii. 
Anaesthetic Formulation
The solubility of Propofol in water is low, approximately 0.154 mg/mL. a. 
Both marketed formulations are prepared as oil-in-water emulsions, 
with most of the Propofol being solubilised in the lipid phase. 
Emulsion formulations are problematic because the lipid components 
readily support microbial growth. Captisol-Enabled Propofol uses the 
novel solubilising agent, Captisol® (sulphobutyl ether-ß-cyclodextrin) 
to provide a true aqueous solution. This formulation minimises the 
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potential for an allergic reaction, reduces microbial growth potential 
and eliminates the need for a lipid component in the formulation. 
The new formulation is fat free with equivalent pharmacokinetics 
and pharmacodynamics as the currently marketed products (www.
Cydexinc.com).
Captisol-Enabled Sertraline oral solution - The First Aqueous Oral iii. 
Sertraline Solution for the treatment of depression
CyDex, Inc., a leader in innovative drug delivery technologies, has a. 
developed an aqueous formulation of this widely-used SSRI, Captisol-
Enabled Sertraline Oral Solution. It is complexed with Captisol in 
an aqueous based formulation. Captisol effectively solubilises and 
taste-masks sertraline HCl in water at the concentration present in 
the marketed formulation (equivalent to 20 mg/mL sertraline). The 
Captisol-Enabled formulation is a pleasant tasting solution. Captisol-
Enabled® Sertraline oral solution is the first aqueous oral solution of 
sertraline (www.Cydexinc.com).
CyDex Licenses Captisol® to Proteolix - Promising Oncology iv. 
Compound
CyDex granted Proteolix global rights to Captisol for a formulation a. 
of PR-171 – a novel proteasome inhibitor derived from the natural 
product epoxomicin. PR-171, also known as carfilzomib, is potent on 
heme tumor cell lines and induces programmed cell death in multiple 
myeloma cells taken from patients, including those that are resistant to 
current therapies. The compound is currently in Phase I clinical trials 
at six leading oncology centres in the United States and Canada. These 
trials are designed to measure the safety and tolerability of PR-171 in 
multiple myeloma and lymphoma patients and to describe preliminary 
evidence of anti-tumor responses (www.Cydexinc.com).
Silicones: f. Silicones belong to broad family of specialty chemicals that is not 
limited to the well-known cyclomethicone, dimethicone and simethicone. 
Silicones include volatile liquids and nonvolatile siloxane fluids of different 
viscosities, as well as siloxane copolyols (emulsifiers), siloxane elastomeric 
gels and siloxane waxes (Sene et al, 2002). The diversity of these materials 
is reflected by the variety of benefits provided and the versatility of silicone 
formulations. Silicone polymers provide a number of unique attributes that 
are due to their distinct physicochemical properties. As silicone polymers 
have unique properties, they are used in pressure sensitive adhesive (PSA) 
applications and as a matrix in transdermal drug delivery systems (TDDS) 
and wound care. They are also useful as additives in solid dosage forms, 
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as process aid or hydrophobisation agent for tablets. More recently, a 
new class of excipient based on silicone has been introduced in topical 
formulation. Silicones meet the increasing demand of pharmaceutical 
industry for novel synthetic excipients. Although silicone excipients do 
not contain preservatives, organic plasticisers, antioxidants, tackifiers or 
stabilizers (which make their composition simpler compared with other 
types of polymer), their polymeric structure must be fully characterized to 
support pharmaceutical use (Sene et al, 2002).
1.8 Recent Patents On Novel Excipients
Joan cucala Escoi published a patent (US20050031862 A1 10, Feb, 2005) 
entitled modified calcium phosphate excipient. The present invention is based 
on the discovery that calcium phosphate can be modified with a fatty acid 
wax and further such a modified calcium phosphate can provide advantageous 
properties. Accordingly, a first aspect of the invention relates to an excipient 
composition comprising calcium phosphate modified with a fatty acid wax, 
wherein a weight ratio of calcium phosphate to wax is within the range of 
50:50 to 95:5, respectively. The excipient composition is generally provided 
in a free flowing particulate form and the fatty acid wax is generally selected 
from palmitic acid, behenic acid, stearic acid, glyceryl behenate, glyceryl 
palmitostearate, hydrogenated castor oil, and mixtures thereof. The particles 
generally have an average size in the range of 20 to 1000 microns, typically 
50 to 500 microns, and in some embodiments from 125 to 250 microns. The 
calcium phosphate is normally an anhydrous dibasic calcium phosphate (Joan 
Cucala Escoi et al, 2005).
Gorgegoan published a patent (EP1697050A2, Sep 6, 2006) entitled 
Fiber rich fraction (FRF) of trigonella foenum-graceumseeds and its use as 
a pharmaceutical excipient. The present invention relates to a novel solvent 
free process of obtaining an insoluble fiber rich fraction from Trigonella 
Foenum-graceum seeds. The invention further relates to the fraction obtained 
from Trigonella Foenum-graceum seeds, having at least 50% of dietary fiber 
with a ratio of insoluble dietary fiber to soluble dietary fiber greater than 0.8 
and a protein content not more than 10 weight % with a viscosity greater 
than 10000 cps at 2% w/v concentration. The invention also relates to the 
process of purifying the fiber rich fraction to obtain a highly purified fiber rich 
fraction. The invention further discloses use of FRF or highly purified FRF as a 
pharmaceutical excipient in various pharmaceutical dosage forms (Gorgegoan 
etal, 2006).
Vincent green published a patent (US 2006/0008521 A1, Jan, 2006) entitled 
Tablet excipient. This invention relates to a composition comprising physically 
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modified, partially pregelatinized starch, which is useful as a multi-functional 
excipient for solid dosage forms, a method of making such composition, and 
solid dosage forms prepared using the composition. The starch composition 
according to this invention is a multi-functional excipient, which possesses 
excellent binding, disintegrating, and flow properties. It is also capable of 
accelerating drug dissolution from a solid dosage form (Vincent green et al, 
2006).
Romain Callaird published a patent (US20110076326, March 31, 2011) 
entitled modified protein excipient for delayed-release tablet. The present 
invention relates to the delayed release of molecules when formulated in a 
compressed tablet that is protein-based of which the protein’s isoelectric point 
has been modified in order to reduce solubility and swelling. Particularly, the 
invention relates to tablets that comprise an excipient comprising chemically-
modified food proteins such as soy proteins or β-lactoglobulin useful for 
delaying release of an active ingredient, namely a pharmaceutical drug or a 
probiotic (Romain Callaird et al, 2011)
Gordon Bardley published a patent (US8226967 B2, July 24, 2012) entitled 
Surface active proteins as excipients in solid pharmaceutical formulations. The 
invention provides a method for utilising surface active proteins as excipients 
in pharmaceutical technology, particularly in galenics. The hydrophobins 
may be used either by admixture to pharmaceutically utilized polymers and 
compounds, by incorporation into/formation of a matrix or by coating of 
galenic forms to achieve a modulation of release kinetics. The pharmaceutical 
form to be treated with the method according to the present invention can be 
designated for oral application or other routes of administration (e.g. rectal 
application). Examples for galenic forms according to the present invention 
are capsules, pills, tablets, matrix tablets, microgranules and suppositories, but 
not limited to these (Gordon Bardley et al, 2012).
2 CONCLUSION
The world of excipients has moved well beyond just improving the stability 
of drugs, to creating a total solution for manufacturers and ultimately, 
patients. Synthetic excipients represent a versatile class of materials that have 
been utilized in the development of different pharmaceutical formulations. 
Coprocessing could hold the key to a successful future for synthetic excipients 
by ushering in a new class of multifunctional compounds. Excipients can be 
physically modified to enhance its properties and to improve its performances. 
It can also be chemically modified to obtain a very wide range of new 
properties that can play an important role in the formulation of smart drug 
delivery systems.






Journal of Pharmaceutical Technology, Research and Management (JPTRM), Volume 1, May 2013
REFERENCES
Abbas, K.A. (2010). “Modified Starches and Their Usages in Selected Food Products: A review 
Study”, J Agri Sci, Vol. 2(2), pp.90-100. 
Bansal, A.K.and Nachaegari, S.K. (2004) “Coprocessed excipient for solid dosage form”. 
Pharmaceutical Technology, pp. 52-64.
Bharate, S.S. (2010) “Interactions and incompatibilities of pharmaceutical excipients with active 
pharmaceutical ingredients: a comprehensive review”, Journal of Excipients and Food 
Chemicals, Vol 1(3), pp.3-26.
Blecher, L. (1993) “Pharmaceutical Excipients: Producers and Users strengthen their Voice”, 
Pharmaceutical Technology, Vol 17(2), pp. 38–39.
Brewster, M.E. and Loftsson, T. (2007) “Cyclodextrins as Pharmaceutical Solubilizers”, Advanced 
Drug Delivery Reviews, Vol 59, pp. 645–666. http://dx.doi.org/10.1016/j.addr.2007.05.012
Buckton, G. (2008) “Excipients and Delivery systems for Pharmaceutical Formulation”, Royal Society 
of Chemistry, Vol 34(4), pp. 373-383.
Chakraborty, S., Shukla, D., Vuddanda, P.R., Mishra, B. and Singh, S. (2010) “Utilization of adsorption 
technique in the development of oral delivery system of lipid based nanoparticles”, Colloids 
and Surfaces B: Biointerfaces, Vol 81, pp. 563-69.
 http://dx.doi.org/10.1016/j.colsurfb.2010.07.058
Chang, E.I. (2011) “Vascular Anastomosis using controlled phase transition in polaxamer gels”, 
Nature Medicine, Vol 17, pp. 1147-1152. http://dx.doi.org/10.1038/nm.2424
Chaudhary, P.D., Pathak, A.A. and Desai, U. (2012) “A Review: Co processed Excipients-An 
Alternative to Novel Chemical entities”, International Journal of Pharmaceutical and Chemical 
Sciences, Vol 1(4), pp.1480-1498.
Chaudhary, S.A., Chaudharya, A.B. and Mehta T.A. (2010) “Excipients Updates for Orally 
Disintegrating Dosage Forms”, International Journal of Research in Pharmaceutical Sciences, 
Vol 1(2), pp.103-107.
Chougule, A.S., Dikpati, A. and Trimbake T. (2012) “Formulation development of coprocessed 
excipients”, Journal of Advanced Pharmaceutical Sciences, Vol 2(2), pp.231-249.
David, S., Pitard, B., Benoita, J.P. and Passirania, C. (2010) “Non-viral Nanosystems for Systemic 
sIRNA Delivery”, Pharmacological Research, Vol 62, pp. 100–114. 
 http://dx.doi.org/10.1016/j.phrs.2009.11.013
El-Barghouthi, M., Eftaiha, A., Rashid, I., Al-Remawi, M. and Badwan, A. (2008) “A novel super 
disintegrating agent made from physically modified chitosan with silicon dioxide”, Drug 
Development and Industrial Pharmacy, Vol 34(4), pp. 373-83.
 http://dx.doi.org/10.1080/03639040701657792
Ender, K., Cabelka, T., Jacob, K., Denomme, D. and Wallick, D. (2007) “A New Hypromellose 
Excipient for Direct Compression Controlled Release Applications”, American Association of 
Pharmaceutical Scientists Annual Meeting Abstract # 002440.
Flores, L.E., Arellano, R.L. and Esquivel, J.J.D. (2000) “Study of load capacity of Avicel PH200 and 
cellactose, two direct-compression excipients using experimental design”, Drug Development 
and Industrial Pharmacy, Vol 26(4), pp. 465-469. http://dx.doi.org/10.1081/DDC-100101256
Gohel, M.C. (2005) “A review of directly compressible excipients”, Journal of Pharmaceutical 
Sciences, Vol 8(1), pp.76-93.







Journal of Pharmaceutical Technology, Research and Management (JPTRM), Volume 1, May 2013
Gordon Bardley (2012). “Surface active proteins as excipients in solid pharmaceutical formulations”.
US Patent (US8226967 B2) July 24 2012. 
Gorgegoan (2006) “Fiber rich fraction of trigonella foenum-graceum seeds and its use as a 
pharmaceutical excipient”. US Patent (EP1697050A2) Sep 6, 2006.
Goyanes, A., Souto, C. and Pacheco R.M. (2011) “Co processed MCC-Eudragit E excipients for 
extrusion–spheronization”, European Journal of Pharmaceutics and Biopharmaceutics, 
Vol.79, pp. 658–663. http://dx.doi.org/10.1016/j.ejpb.2011.07.013
Hapgood, K.P., Tan, M.X.L. and Chow, D.W.Y. (2009) “A method to predict nuclei size distributions 
for use in models of wet granulation”, Advanced Powder Technology, Vol.20, pp. 293–297. 
http://dx.doi.org/10.1016/j.apt.2008.09.004
Huang, Y., Khanvilkar, K.H., Moore, A.D. and Hilliard, M. (2003) “Effects of Manufacturing Process 
Variables on In vitro Dissolution Characteristics of Extended-Release Tablets formulated with 
Hydroxypropyl Methylcellulose”, Drug Development and Industrial Pharmacy, Vol.29(1), 
pp.79-88. http://dx.doi.org/10.1081/DDC-120016686
Joan Cucala Escoi (2005). Modified calcium phosphate excipient.US Patent (20050031862 A1) 10, 
Feb, 2005.
Marwaha, M., Sandhu, D. and Marwaha, R.K. (2010) “Co processing of excipients: a review on 
excipient development for improved tableting performance”, International Journal of Applied 
Pharmaceutics, Vol.2 (3), pp.41-47. 
Medina R., Kumar V. (2006) “Evaluation of cellulose II powders as a potential multifunctional 
excipient in tablet formulations”, International Journal of Pharmaceutics, Vol 322(2), 
 pp.31-35. http://dx.doi.org/10.1016/j.ijpharm.2006.05.033
Michael J.K. (1993) “Spray drying and spray congealing of pharmaceuticals In: Encyclopedia of 
pharmaceutical technology’. Marcel Dekker INC, NY, Vol 14, 207-221.
Michaud, J. (2002) “Starch based excipients for pharmaceutical tablets”, Pharmaceutical Chemistry, 
pp.42-44.
Manudhane K.S., Kim H.Y. and Shangraw R.F (2010). “Tableting properties of a directly compressible 
starch”, Journal of Pharmaceutical Sciences, Vol 58(5), pp.616-620.
 http://dx.doi.org/10.1002/jps.2600580524
Miclea, R.D., Purohit, V.S. and Iyer, S.V (2007) “O-Phospho-L-Serine, Multi-functional Excipient for 
B Domain Deleted Recombinant Factor VIII”, The American Association of Pharmaceutical 
Scientists Vol 9(2), pp.251-259.
Miller, R.W. (1997) “Roller compaction technology In: Handbook of Pharmaceutical Granulation 
Technology”, Parikh D.M. (Ed.), Marcel Dekker. pp. 100–149.
Okimoto, K., Rajewski, R.A., Uekama, K., Jona, J.A. and Stella V.J. (1996) “The interaction of 
charged and uncharged drugs with neutral (HP-beta-CD) and anionically charged (SBE7-beta-
CD) beta-cyclodextrins”, Pharmtech Research, Vol 13(2), pp.256-264.
 http://dx.doi.org/10.1023/A:1016047215907
Parker, A. (2009) “Focus on excipients”, Chemistry Today, Vol 27(1), pp.5-7
Parker, A. (2009) “SYLOID® FP Multifunctional excipients for the pharmaceutical industry”, 
Chemistry Today, Vol 27(5), pp. 1-2.
Patel, R.P., Patel, M.P. and Suthar, A.M. (2009) “Spray drying technology: an overview”, Indian 
Journal of Science and Technology, Vol 2(10), pp. 44-45.
Pawar, S.K. and Vavia, P.R. (2012) “Rice Germ Oil as Multifunctional Excipient in preparation of Self-
Microemulsifying Drug Delivery System (SMEDDS) of Tacrolimus”, American Association of 
Pharmaceutical Scientists, Vol 13(1), pp.255-261.






Journal of Pharmaceutical Technology, Research and Management (JPTRM), Volume 1, May 2013
Pifferi, G. and Restani, P. (2003) “Pharmaceutical Preformulation: the physicochemical properties of 
drug substances”, II Farmaco, Vol 58, pp. 541-550.
 http://dx.doi.org/10.1016/S0014-827X(03)00079-X
Prasanna, R.Y., Jayasri, V., Yasmeen, R.B., Chowdary, H.V. and Satyanandam, S. (2011) “Significance 
of Pharmaceutical Excipients-A Review”, Journal of Innovative trends in Pharmaceutical 
Sciences, Vol 2(6), pp.191-201.
Rashid, I., Al-Remawi, M., Leharne, S.A., Chowdhry, BZ.and Badwan A. (2011) A novel 
multifunctional pharmaceutical excipient: Modification of the permeability of starch by 
processing with magnesium silicate, International Journal of Pharmaceutics, Vol 411, 
pp.18–26. http://dx.doi.org/10.1016/j.ijpharm.2011.03.011
Rashid, I., Al-Remawi , M., Eftaiha, A. and Badwan A. (2008) Chitin-Silicon dioxide Co precipitate 
as a novel superdisintegrant, Journal of Pharmaceutical Sciences, Vol 97(11),pp.4955-4969.
Rashid,I., Al-Remawi, M., Eftaiha, A. and Badwan, A. (2008) Chitin-silicon dioxide co precipitate as 
a novel superdisintegrant, Journal of Pharmaceutical Sciences, Vol 97, pp. 4955–4969.
Retrieved from < URL http://www.contractpharm.com.html>
Retrieved from <URL http://www.Zeusinc.com.html>
Retrieved from <URL http://www.ich.org/LOB/media/MEDIA1957.pdf.html>
Retrieved from <URL http:// www.Captisol.com>
Retrieved from < URL http:// www.colorcon.com>
Retrieved from < URL http:// www.Cydexinc.com>
Reynolds, G., Ingale, R., Roberts, R., Kothari, S., Gururajan, B. (2010) ”Practical application of roller 
compaction process modelling”, Computers and Chemical Engineering, Vol 34, pp.1049–
1057.
Rohokale, S.S., Dhanorkar, YD., Pahuja, V. and Kulkarni, G.T. (2012) “Characterization of selected 
Polysaccharide hydrogels as pharmaceutical excipients”, Journal of Chronotherapy and Drug 
Delivery, 3, Vol 2, pp.41-54.
Romain Callaird (2011). “Modified protein excipient for delayed-release tablet”.US Patent (0076326) 
31MARCH.
Russell, R. (2004). “Synthetic Excipients Challenge All-Natural Organics”. Pharmaceutical 
Technology, Vol 28, pp. 38-50.
Sene, C., Dupont, A. and Crowning, D. Characterising polymeric excipients. Innovations in 
Pharmaceutical Technology, pp.81-91.
Sene, C., Neun. D, Tan-sen hee, L. and Ulman, K. (2002) “Silicones as excipients for topical 
pharmaceutical applications”. Dow corning internal document form Vol. 52-1034-01.
Sherwood, BE. and Becker, JW. (1998). “A New Class of High Functionality Excipients: Silicified 
Microcrystalline Cellulose”, Pharmaceutical Technology, Vol. 22(10), pp.78-88.
Sheskey, PJ. and Williams, DM. (1996) “Comparison of Low-Shear and High-Shear Wet Granulation 
Techniques and the Influence of Percent Water Addition in the Preparation of a Controlled-
Release Matrix Tablet Containing HPMC and a High-Dose, Highly Water-Soluble Drug”. 
Pharmaceutical Technology, vol. 20, pp. 81-92.
Steinberg, M., Brozelleca, J.F., Enters, E.K., Kinoshita, F.K., Loper, A., Mitchell, D.B., Tamulinas, 
C.B. and Weiner, M.L. (1996). “A new approach to the safety assessment of pharmaceutical 
excipients”, Regulatory Toxicology and Pharmacology, 24, pp.149-154
 http://dx.doi.org/10.1006/rtph.1996.0120
Steinberg, M., Blecher, L. and Mercill, A. (2001) “From Inactive Ingredients to Pharmaceutical 
Excipients”, Pharmaceutical Technology, Vol. 25(7), pp. 62–64.







Journal of Pharmaceutical Technology, Research and Management (JPTRM), Volume 1, May 2013
Velagaleti, R. (2009). “Excipient Innovation and Regulatory Acceptance for Use in Drug Products–
Solubilizer Solutol® HS 15 Case Study”. Presented at: Annual Meeting of the American 
Association of Pharmaceutical Scientists. Los Angeles, CA, USA, November (2009).
Vincent green (2006). Tablet excipient US patent (0008521 A1) JAN 2006.
Vuorinen, S., Heinamaki, J., Antikainen, O., Lahcini, M., Repo, T. and Yliruusi, J. (2009). “Sugar 
End-Capped Poly-D, L-lactides as Excipients in Oral Sustained Release Tablets”, American 
Association of Pharmaceutical Sciences, Vol. 10(2), pp.566-573.
York, F.P. and Rowe, R.C. (2000). “Process control and scale-up of pharmaceutical wet granulation 
processes: a review”, European Journal of Pharmaceutics and Biopharmaceutics, Vol. 52, pp. 
269–277.
York, P. (1992). “Crystal Engineering and particle design for the Powder Compaction Process”, Drug 
Development and Industrial Pharmacy, Vol. 18(6), pp.677–721.
 http://dx.doi.org/10.3109/03639049209058558
Zeleznik, J.A. and Renak, J. (2004). “High Functionality Excipients (HFE) –PROSOLV® SMCC as 
an Effective Strategy for Generic Drug Formulation”, Business Briefing: Pharma Generics, 
pp. 1-4.
06JPTRM.indd   107 1/26/2015   1:58:05 PM
